Physical activity (PA) is a cornerstone of type 2 diabetes (T2D) treatment. In the U.S, Latinos bear a disproportionate cardio-metabolic disease burden from T2D. The aim of this study was to determine levels and patterns of PA among free-living Latino adults with T2D comparing a ubiquitous consumer device with an established accelerometry method.
Participants (57 women and 31 men, BMI (kg/m2) 32.2±7.9 and 29.9±4.5, waist circumference (WC cm) 97.1±30.1 and 93.7±33.0, and HbA1C% 8.0±2.0 and 8.1±1.8, respectively) wore a research device (Actigraph, wGT3X-BT, AG) on the dominant hip and a consumer device (Fitbit Charge 2™, FB) on the non-dominant wrist to monitor daily activity for one week [outcome measures estimated by steps and energy expenditure (EE)].
AG median steps/weekday (M-F) was 6990 (range 1091-25884) compared to 9329 (288-31669) using the FB data (p≤0.01). Both devices recorded higher number of steps on weekdays compared to weekends [AG 5608 (1066-19892) and FB 7577 (1023-23603), both p≤0.05]. This corresponded to activity-related energy-expenditure of 442 (63-1821) kcals/weekday and 361 (58-1396) kcals/weekend using AG and 2344 (1135-5802) kcals/weekday and 2178 (1378-4930) kcals/weekend by FB (including resting metabolic rate). AG and FB data were highly correlated to each other for daily steps (r’s>0.7, p’s<0.01) but not for estimated EE. Men were more active than women on average and maintained their PA throughout the week. However, women decreased their PA on weekends (by around 1700 steps or 130 kcals/day by AG) while their weekday PA was negatively correlated with BMI and WC (p<0.05). Using AG, only 2 participants reached 6,000 steps in an hour at least twice during the week and 58% never reached 3,000 steps in 30 minutes on any day of the week (a common moderate to vigorous intensity PA goal).
In conclusion, to incentivize PA in Latino adults with T2D, considerations need to be made of the timing of measurements (weekdays versus weekends), gender and technologies used.
W.C. Bevier: Research Support; Self; Eli Lilly and Company. N.M. Glantz: Research Support; Self; Eli Lilly and Company. C.B. Hoppe: Research Support; Self; Eli Lilly and Company. J. Morales: Research Support; Self; Eli Lilly and Company. A.J. Larez: Research Support; Self; Eli Lilly and Company. M.M. Conneely: Research Support; Self; Eli Lilly and Company. K.Y. Chen: None. D. Kerr: Advisory Panel; Self; Ascensia Diabetes Care, Novo Nordisk A/S, Sanofi. Research Support; Self; Lilly Diabetes. Stock/Shareholder; Self; Glooko, Inc.
Eli Lilly and Company